Table 2.

Determinants of cSS presence

	Global P-valuesa	Group D vs. group A			Group D vs. group C
		ORa	95% CI	P	ORa	95% CI	P
Age (per year)	<0.001	1.09	1.05, 1.14	<0.001	1.04	1.00, 1.09	0.058
Male	<0.001	1.70	0.78, 3.71	0.183	1.43	0.64, 3.20	0.379
Hypertension	<0.001	2.64	0.77, 9.06	0.123	2.47	0.71, 8.56	0.154
Total cholesterol (per mg/dL)	<0.001	1.00	0.99, 1.01	0.735	1.01	1.00, 1.02	0.366
Antithrombotic use	<0.001	0.93	0.41,2.10	0.855	0.76	0.34, 1.73	0.517
Statin use	<0.001	1.88	0.80, 4.40	0.146	1.41	0.59, 3.34	0.436
APOE ε2bAny ε2 vs. ε33	<0.001	2.73	0.86,8.67	0.088	2.65	0.82,8.55	0.103
APOE ε4cAny ε4 vs. ε33	<0.001	5.19	2.04,13.15	0.001	3.47	1.35,8.92	0.010
Extensive WMH	<0.001	1.41	0.53, 3.78	0.494	0.87	0.32, 2.39	0.794
Lacunes	<0.001	1.21	0.41, 3.61	0.731	1.00	0.33, 3.05	0.996
TCBV	<0.001	0.97	0.86, 1.10	0.645	0.96	0.85, 1.08	0.476

Note: For description of groups see Table 1. OR: odds ratio; CI: confidence interval; APOE: apolipoprotein E; cSS: cortical superficial siderosis; TCBV: total cranial brain volume; WMH: white matter hyperintensities.

^aModel is adjusted for age at MRI, sex and cohort.

^bCoded as 0 for ε33 and 1 for any ε2.

^cCoded as 0 for ε33 and 1 for any ε4.